<DOC>
	<DOC>NCT02042183</DOC>
	<brief_summary>A study of the efficacy and safety of Lubiprostone in pediatric subjects aged ≥ 6 Years to &lt; 18 years diagnosed with Functional Constipation</brief_summary>
	<brief_title>Efficacy and Safety of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to &lt; 18 Years With Functional Constipation</brief_title>
	<detailed_description>To assess the efficacy, safety, and pharmacokinetics (PK) of oral lubiprostone 12 or 24 mcg capsules dosed twice daily (BID) (based on subject body weight at baseline) as compared to matching placebo BID, when administered orally for 12 weeks in pediatric subjects with functional constipation.</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Medicallyconfirmed diagnosis of Functional Constipation per Rome III Diagnostic Criteria for Childhood Functional Constipation At least 6 years of age but less than 18 years of age at the time of randomisation Only stable dose of selective serotonin reuptake inhibitors (SSRIs), serotoninspecific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors are allowed if subject is taking antidepressants Any gastrointestinal (GI) condition, other than constipation and/or irritable bowel syndrome (IBS), affecting GI motility or defecation Untreated faecal impaction at the time of screening Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>